Moderna (MRNA) Non-Current Assets (2017 - 2026)

Moderna (MRNA) has 10 years of Non-Current Assets data on file, last reported at $5.7 billion in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 3.7% year-over-year to $5.7 billion in Q1 2026; TTM through Mar 2026 was $22.9 billion, a 5.17% decrease from a year earlier, with the FY2025 full-year figure at $5.8 billion, down 4.12% from the prior year.
• Non-Current Assets for Q1 2026 stood at $5.7 billion, down from $5.8 billion in the prior quarter.
• Over the last five years, Non-Current Assets for MRNA reached as high as $12.5 billion in Q2 2022 and fell as low as $5.5 billion in Q3 2025.
• Historically, Non-Current Assets has averaged $8.4 billion across 5 years, with a median of $7.1 billion in 2024.
• Across the five-year window, Non-Current Assets jumped 1036.13% in 2022 and tumbled 46.66% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $12.4 billion in 2022, then sank by 34.81% to $8.1 billion in 2023, then retreated by 25.4% to $6.0 billion in 2024, then slipped by 4.12% to $5.8 billion in 2025, then dropped by 1.31% to $5.7 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $5.7 billion in Q1 2026, $5.8 billion in Q4 2025, and $5.5 billion in Q3 2025.